EPISODE 162 | RELEASED April 11, 2022

Tanovea: The First FDA-Approved Dog Lymphoma Treatment | Dr. Douglas Thamm

Born in a human drug research company, Tanovea (rabacfosadine) is now making history treating lymphoma in dogs.

SHOW NOTES

Lymphoma in dogs is very responsive to chemotherapy, but it also often relapses. Each time a dog comes out of remission, the cancer often gets harder to beat. Because of this, researchers are constantly looking for new treatments that can either get long-lasting results from the start or be used to beat back the cancer in those difficult cases.

Meet rabacfosadine, known by the brand name Tanovea. This drug is an injectable chemotherapeutic that just became the first ever FDA-approved treatment for lymphoma in dogs. Dr. Douglas Thamm, an oncologist at Colorado State University, has been working with Tanovea through most of its existence, and tells us all about how this drug came to be, how it works, and what we know so far about when it is most useful.

Links Mentioned in Today’s Show:

T-CHOP NAÏVE CANINE LYMPHOMA STUDY at Colorado State

Clinical Trials at University of Wisconsin

Clinical Trials at Oregon State University

Hosted By

SUBSCRIBE ON YOUR FAVORITE PLATFORM

Topics

Advertisement

Advertisement

Did You Find This Helpful? Share It with Your Pack!

Share on social media, download a PDF, print this out, or send this in an email to your veterinarian.


Advertisement

Editor's Picks

CATEGORY

Advertisement

RELATED EPISODES